Iranian Journal of Pathology

Do Fibroblast Growth Factor Receptor (FGFR) 2 and 3 Proteins Play a Role in the Prognosis of Invasive Urothelial Bladder Carcinoma?

Document Type : Original Research

Authors

Shereen Fathy Mahmoud 1
Nanis Shawky Holah 1
Alshimaa mahmoud Alhanafy 2
Marwa Mohammed Serag El-Edien 1

1 Department of Pathology, Faculty of Medicine, Menoufia University, Minufiyah, Egypt

2 Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Menoufia University, Minufiyah, Egypt

https://doi.org/10.30699/ijp.2023.2012115.3180
Abstract
Background & Objective: Bladder carcinoma ranks second in prevalence among males in Egypt. As a family of tyrosine kinases, fibroblast growth factor receptor (FGFR) dysregulation has been linked to some malignancies in humans. The aim of this study is to analyze the clinicopathological data of patients while investigating FGFR2 and FGFR3 immunohistochemical expression in invasive urothelial bladder carcinoma.
Methods: This retrospective cross-sectional study included 60 invasive urothelial carcinoma (UC) cases in the Pathology department, Faculty of Medicine, Menoufia University, from 2009 to 2020. All biopsies were stained for FGFR2 and FGFR3 antibodies. Complete clinical data were available for 44 patients treated and followed in clinical oncology and nuclear medicine departments.
Results: Advanced stage and high grade are significantly correlated with FGFR2 positivity (P=0.048 and 0.044, respectively). Cases presented with Perineural invasion showed a higher percentage of FGFR2 (P=0.023). There is a significant indirect linear correlation between FGFR3 expression and lymph node positivity (r= -0.265, P=0.041).
Conclusion: High FGFR2 expression was associated with poor prognostic parameters, while high FGFR3 expression was associated with good prognostic parameters, and this might highlight the importance of FGFR-targeted therapy as FGFR2 antagonist and FGFR3 agonist for the treatment of urothelial carcinoma patients.

Keywords

FGFR2
FGFR3
Immunostaining
Prognosis
Urothelial carcinoma

Subjects

  1. WHO: World Cancer. In: Cancer GIAFRo (Ed): Globocan 2020, Globocan 2020: International Agency For Research on Cancer.
  2. Siegel RL, Miller KD, Wagle NS and Jemal A. Cancer statistics 2023, CA Cancer J Clin. 2023;73:17-48. [DOI:10.3322/caac.21763] [PMID]
  3. WHO: Egypt Cancer. In: Cancer GIAFRo (Ed): Globocan 2020, Globocan 2020: International Agency For Research on Cancer.
  4. Dai S, Zhou Z, Chen Z, Xu G, Chen Y. Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors. Cells 2019;8. [DOI:10.3390/cells8060614] [PMID]
  5. Chen L, Fu L, Sun J, Huang Z, Fang M, Zinkle A,  et al. Structural basis for FGF hormone signalling. Nature; 2023; 618, 862-70. [DOI:10.1038/s41586-023-06155-9] [PMID]
  6. Tiong KH, Mah LY, Leong C-O. Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis. 2013;18:1447-68. [DOI:10.1007/s10495-013-0886-7] [PMID]
  7. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10(2):116-29. [DOI:10.1038/nrc2780] [PMID]
  8. Al-Obaidy KI and Cheng L. Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder. J Clin Pathol. 2021;74:491-495. [DOI:10.1136/jclinpath-2020-207115] [PMID]
  9. Weickhardt AJ, Lau DK, Hodgson-Garms M, Lavis A, Jenkins LJ, Vukelic N, Ioannidis P, Luk IY, Mariadason JM. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer. BMC Cancer. 2022;22(1):1-1. [DOI:10.1186/s12885-022-09478-4] [PMID]
  10. Al-Obaidy KI and Cheng L. Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder. J Clin Pathol. 2021;74:491-5. [DOI:10.1136/jclinpath-2020-207115] [PMID]
  11. Mojarrad M, Moghbeli M. Genetic and molecular biology of bladder cancer among Iranian patients. Mol Genet Genomic Med. 2020;8(6):e1233. [DOI:10.1002/mgg3.1233] [PMID]
  12. Zhang, S, Wang, J, Zhang, X, Zhou, F. Tumor-infiltrating CD8+ lymphocytes predict different clinical outcomes in organ-and non-organ-confined urothelial carcinoma of the bladder following radical cystectomy. Peer J. 2017;5,e3921. [DOI:10.7717/peerj.3921] [PMID]
  13. Moch, H, Humphrey, P A, Ulbright, T. M, Reuter, V. E. Book WHO Classification of Tumours of the Urinary system and Male Genital Organs; International Agency for Research on Cancer: Lyon, 2016. [DOI:10.1016/j.eururo.2016.02.028] [PMID]
  14. Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, et al. AJCC cancer staging manual. Amin MB, Edge SB, Greene FL, editors. New York: springer; 2017 Jan.
  15. Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, et al. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol. 2015;1(6):778-84. [DOI:10.1001/jamaoncol.2015.2378] [PMID]
  16. Damian Szatkowski, Andrzej Hellmann; The Overexpression of KIT Proto-Oncogene in Acute Leukemic Cells Is Not Necessarily Caused by the Gene Mutation. Acta Haematol. 1 November 2014; 133 (1): 116-23. [DOI:10.1159/000360214.] [PMID]
  17. Al-Obaidy KI and Cheng L. Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder. J Clin Pathol. 2021; 74:491-5 [DOI:10.1136/jclinpath-2020-207115] [PMID]
  18. IKEDA J, Ohe C, Yoshid T, Saito R, Tsuta K and Hidefumi K. CD155 immunohistochemical expression in upper tract urothelial carcinoma predicts poor prognosis. Oncol Lett, 2022, 24: 414. [DOI:10.3892/ol.2022.13534] [PMID]
  19. Di Martino E, Tomlinson DC, Williams SV and Knowles MA. A place for precision medicine in bladder cancer: targeting the FGFRs. Future Oncol. 2016; 12(19),2243-63 [DOI:10.2217/fon-2016-0042] [PMID]
  20. Zaravinos A, Volanis D, Lambrou GI, Delakas D, Spandidos DA. Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder. Oncol. Rep. 2012; 28(4), 1159-66. [DOI:10.3892/or.2012.1948] [PMID]
  21. Ceccarelli S, Bei R, Vescarelli E, D’Amici S, Di Gioia C, Modesti A, et al. Potential Prognostic and Diagnostic Application of a Novel Monoclonal Antibody Against Keratinocyte Growth Factor Receptor. Mol Biotechnol. 2014; 56, 939-952. [DOI:10.1007/s12033-014-9773-x] [PMID] []
  22. di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol. 2012;2012. [DOI:10.1155/2012/429213] [PMID]
  23. De Medina SG, Popov Z, Chopin DK, Southgate J, Tucker GC, Delouvee A, Thiery JP, Radvanyi F: Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas. Oncogene. 1999; 18:5722e5726 [DOI:10.1038/sj.onc.1202958] [PMID]
  24. Hussain, S. A., Palmer, D. H., Syn, W., Sacco, J. J., Greensmith, R. M., Elmetwali, T., Aachi, V., Lloyd, B. H., Jithesh, P. V., Arrand, J., Barton, D., Ansari, J., Sibson, D. R., James, N. D."Gene expression profiling in bladder cancer identifies potential therapeutic targets". International Journal of Oncology; 2017, 50.4: 1147-1159. [DOI:10.3892/ijo.2017.3893] [PMID]
  25. Narla ST, Bushnell DS, Schaefer CM, Nouraie M, Tometich JT, Hand TW, Bates CM, Loss of Fibroblast Growth Factor Receptor 2 (FGFR2) Leads to Defective Bladder Urothelial Regeneration after Cyclophosphamide Injury, The American Journal of Pathology, 2021, Volume 191, Issue 4, Pages 631-651, [DOI:10.1016/j.ajpath.2020.12.011] [PMID]
  26. Loriot Y., Necchi A., Park S.H., Garcia-Donas J., Huddart R., Burgess E., Fleming M., Rezazadeh A., Mellado B., Varlamov S., et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N. Engl. J. Med. 2019;381:338-348. [DOI:10.1056/NEJMoa1817323] [PMID]
  27. Garje R., An J., Obeidat M., Kumar K., Yasin H.A., Zakharia Y. Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer: Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer. Oncologist. 2020;25:e1711-9 [DOI:10.1634/theoncologist.2020-0334] [PMID]
  28. Andreassen B.K., Grimsrud T.K., Haug E.S. Bladder cancer survival: Women better off in the long run. Eur J Cancer. 2018;95:52-8. [DOI:10.1016/j.ejca.2018.03.001] [PMID]
  29. 30- Uhlig A, Seif Amir Hosseini A, Simon J, Lotz J, Trojan L, Schmid M, et al. Gender specific differences in disease-free, cancer specific and overall survival after radical cystectomy for bladder cancer: A systematic review and meta-analysis. J Urol. 2018;200:48-60. [DOI:10.1016/j.juro.2017.11.150] [PMID]
  30. Kang H W, Kim Y, Jeong P, Park C, Kim W T, Ryu D H, et al. Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status. Oncol Lett. di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol. 2012 Jul 31;2012. [DOI:10.3892/ol.2017.6621] [PMID]
  31. van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M, Hamdy FC, Catto JW. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009;55(3):650-8. [DOI:10.1016/j.eururo.2008.06.013] [PMID]
  32. Van Rhijn BW, Van Der Kwast TH, Liu L et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol. 2012; 187(1), 310-4. [DOI:10.1016/j.juro.2011.09.008] [PMID]
  33. Poyet C, Hermanns T, Zhong Q, Drescher E, Eberli D, Burger M, et al. Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer. Oncol Lett. 2015;10(5),2753-60. [DOI:10.3892/ol.2015.3691] [PMID]
  34. Nagy AA, Darweish H, Hamdey HM, Elkalla R, Abdu-allah H. Factors Affecting Survival in Egyptian Patients Suffering from Urinary Bladder Cancer: A Multicenter Retrospective Study. J Cancer Sci Ther. 2018;10:031-5. [DOI:10.4172/1948-5956.1000513]
  35. Taguchi S, Nakagawa T, Hattori M, Niimi A, Nagata M, Kawai T, Fukuhara H, Nishimatsu H, Ishikawa A, Kume H, Homma Y. Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy. Jpn J Clin Oncol. 2013 Sep;43(9):923-8 [DOI:10.1093/jjco/hyt096] [PMID]
  36. Mitra AP, Bartsch CC, Bartsch G, Miranda G, Skinner EC, Daneshmand S. Does presence of squamous and glandular differenriation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urol Oncol. 2014; 32:117-27. [DOI:10.1016/j.urolonc.2012.08.017] [PMID]
  37. Kucuk U, Pala EE, Cakır E, Sezer O, Bayol U, Divrik RT, Cakmak O. Clinical, demographic and histopathological prognostic factors for urothelial carcinoma of the bladder. Cent European J Urol. 2015; 68(1):30-6. [DOI:10.5173/ceju.2015.01.465] [PMID]
  38. Sevillano Fernández E, Madurga de Lacalle R, Rodriguez Moreno JF, Barquín García A, Yagüe Fernández M, Navarro Alcaraz P, et al. Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients. J Clin Med. 2022; 11(15):4483. [DOI:10.3390/jcm11154483] [PMID]
Iranian Journal of Pathology
Volume 19, Issue 1
Winter 2024
Pages 81-88

  • Receive Date 02 October 2023
  • Revise Date 07 November 2023
  • Accept Date 07 November 2023

Home

Guide for Authors

Submit Manuscript

Contact Us